Tokyo - Delayed Quote JPY
Stella Pharma Corporation (4888.T)
335.00
+9.00
+(2.77%)
As of 10:45:01 AM GMT+9. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Koki Uehara | President & Chairman | -- | -- | 1977 |
| Mr. Toshimitsu Hayashi | GM of Pharmaceutical Affairs & Clinical Development Department and Director | -- | -- | 1981 |
| Mr. Takahiro Kido | GM of Corporate Planning Department & Director | -- | -- | 1973 |
Stella Pharma Corporation
ORIX Kouraibashi Building
3-2-7 Korai-bashi Chuo-ku
Osaka, 541-0043
Japan
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 44
Description
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
Corporate Governance
Stella Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 9, 2025 at 10:59 AM UTC
Stella Pharma Corporation Earnings Date
Recent Events
Recent Events Information Not Available